Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between co
- PDF / 605,110 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 141 Views
ORIGINAL ARTICLE
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine Taku Kikuchi1 · Takehiko Mori1 · Chikako Ohwada2,3 · Masahiro Onoda4 · Hiroaki Shimizu5 · Hiroki Yokoyama6 · Makoto Onizuka7 · Yuya Koda1 · Jun Kato1 · Yusuke Takeda2 · Yutaro Hino2 · Tatsuzo Mishina2 · Emiko Sakaida2 · Katsuhiro Shono4 · Yuhei Nagao4 · Akira Yokota4 · Kana Matsumoto8 · Kunihiko Morita8 · Shinichiro Okamoto1 · Kanto Study Group for Cell Therapy (KSGCT) Received: 13 April 2020 / Revised: 3 August 2020 / Accepted: 28 August 2020 © Japanese Society of Hematology 2020
Abstract Busulfan (Bu) has been used in combination with fludarabine (Flu; BuFlu) or cyclophosphamide (Cy; BuCy) as conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). This multi-institutional prospective study compared pharmacokinetic (PK) parameters of Bu between BuFlu and BuCy. Plasma Bu concentrations were measured by high-performance liquid chromatography at the first dose of the first and fourth days of intravenous Bu administrations (total of 16 doses of 0.8 mg/kg). Thirty-seven patients were evaluable (BuFlu, N = 18; BuCy, N = 19). The median age was significantly higher in BuFlu. In BuFlu, the median area under the blood concentration–time curve of Bu on the fourth day was 1183 μmol min/L (range 808–1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822–1453), P
Data Loading...
